Home > > Europe And Global Gene Therapy Market- Size, Share, Growth Rate, and Forecast
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: EUROPE GENE THERAPY MARKET 3.1. OVERVIEW 3.2. EUROPE 3.2.1. EUROPE GENE THERAPY MARKET, BY VECTOR 3.2.2. EUROPE GENE THERAPY MARKET, BY INDICATION 3.2.3. EUROPE GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4. EUROPE GENE THERAPY MARKET, BY COUNTRY 3.2.4.1. GERMANY 3.2.4.1.1. GERMANY GENE THERAPY MARKET, BY VECTOR 3.2.4.1.2. GERMANY GENE THERAPY MARKET, BY INDICATION 3.2.4.1.3. GERMANY GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.2. FRANCE 3.2.4.2.1. FRANCE GENE THERAPY MARKET, BY VECTOR 3.2.4.2.2. FRANCE GENE THERAPY MARKET, BY INDICATION 3.2.4.2.3. FRANCE GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.3. U.K. 3.2.4.3.1. U.K. GENE THERAPY MARKET, BY VECTOR 3.2.4.3.2. U.K. GENE THERAPY MARKET, BY INDICATION 3.2.4.3.3. U.K. GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.4. ITALY 3.2.4.4.1. ITALY GENE THERAPY MARKET, BY VECTOR 3.2.4.4.2. ITALY GENE THERAPY MARKET, BY INDICATION 3.2.4.4.3. ITALY GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.5. SPAIN 3.2.4.5.1. SPAIN GENE THERAPY MARKET, BY VECTOR 3.2.4.5.2. SPAIN GENE THERAPY MARKET, BY INDICATION 3.2.4.5.3. SPAIN GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.6. ROE 3.2.4.6.1. ROE GENE THERAPY MARKET, BY VECTOR 3.2.4.6.2. ROE GENE THERAPY MARKET, BY INDICATION 3.2.4.6.3. ROE GENE THERAPY MARKET, BY DELIVERY METHOD CHAPTER 4: GLOBAL GENE THERAPY MARKET, BY VECTOR 4.1. OVERVIEW 4.2. NON-VIRAL VECTORS 4.2.1. NON-VIRAL VECTORS MARKET, BY REGION 4.2.1.1. NORTH AMERICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.2. EUROPE NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.3. ASIA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.3. VIRAL VECTORS 4.3.1. VIRAL VECTORS MARKET, BY REGION 4.3.1.1. NORTH AMERICA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.2. EUROPE VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.3. ASIA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET, BY COUNTRY CHAPTER 5: GLOBAL GENE THERAPY MARKET, BY INDICATION 5.1. OVERVIEW 5.2. NEUROLOGICAL DISEASES 5.2.1. NEUROLOGICAL DISEASES MARKET, BY REGION 5.2.1.1. NORTH AMERICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.2. EUROPE NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.3. ASIA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.3. CANCER 5.3.1. CANCER MARKET, BY REGION 5.3.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 5.3.1.2. EUROPE CANCER MARKET, BY COUNTRY 5.3.1.3. ASIA CANCER MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 5.4. HEPATOLOGICAL DISEASES 5.4.1. HEPATOLOGICAL DISEASES MARKET, BY REGION 5.4.1.1. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.2. EUROPE HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.3. ASIA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.4. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.5. DUCHENNE MUSCULAR DYSTROPHY 5.5.1. DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION 5.5.1.1. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.2. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.3. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.4. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.6. OTHER INDICATIONS 5.6.1. OTHER INDICATIONS MARKET, BY REGION 5.6.1.1. NORTH AMERICA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.2. EUROPE OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.3. ASIA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.4. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET, BY COUNTRY CHAPTER 6: GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD 6.1. OVERVIEW 6.2. IN-VIVO GENE THERAOY 6.2.1. IN-VIVO GENE THERAOY MARKET, BY REGION 6.2.1.1. NORTH AMERICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.2. EUROPE IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.3. ASIA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3. EX-VIVO GENE THERAOY 6.3.1. EX-VIVO GENE THERAOY MARKET, BY REGION 6.3.1.1. NORTH AMERICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.2. EUROPE EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.3. ASIA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY TABLE 75. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF TABLES TABLE 01. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 02. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 03. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 04. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 05. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. EUROPE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 07. EUROPE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 08. EUROPE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 09. EUROPE GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 10. GERMANY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 11. GERMANY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 12. GERMANY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 13. FRANCE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 14. FRANCE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 15. FRANCE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 16. U.K. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 17. U.K. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 18. U.K. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 19. ITALY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 20. ITALY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 21. ITALY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 22. SPAIN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 23. SPAIN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 24. SPAIN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 25. ROE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 26. ROE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 27. ROE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 28. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 29. NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 30. NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 35. NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 40. NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 41. NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 46. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 56. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 57. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 61. NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 62. EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 66. IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 72. NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 73. EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF FIGURES CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: EUROPE GENE THERAPY MARKET 3.1. OVERVIEW 3.2. EUROPE 3.2.1. EUROPE GENE THERAPY MARKET, BY VECTOR 3.2.2. EUROPE GENE THERAPY MARKET, BY INDICATION 3.2.3. EUROPE GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4. EUROPE GENE THERAPY MARKET, BY COUNTRY 3.2.4.1. GERMANY 3.2.4.1.1. GERMANY GENE THERAPY MARKET, BY VECTOR 3.2.4.1.2. GERMANY GENE THERAPY MARKET, BY INDICATION 3.2.4.1.3. GERMANY GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.2. FRANCE 3.2.4.2.1. FRANCE GENE THERAPY MARKET, BY VECTOR 3.2.4.2.2. FRANCE GENE THERAPY MARKET, BY INDICATION 3.2.4.2.3. FRANCE GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.3. U.K. 3.2.4.3.1. U.K. GENE THERAPY MARKET, BY VECTOR 3.2.4.3.2. U.K. GENE THERAPY MARKET, BY INDICATION 3.2.4.3.3. U.K. GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.4. ITALY 3.2.4.4.1. ITALY GENE THERAPY MARKET, BY VECTOR 3.2.4.4.2. ITALY GENE THERAPY MARKET, BY INDICATION 3.2.4.4.3. ITALY GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.5. SPAIN 3.2.4.5.1. SPAIN GENE THERAPY MARKET, BY VECTOR 3.2.4.5.2. SPAIN GENE THERAPY MARKET, BY INDICATION 3.2.4.5.3. SPAIN GENE THERAPY MARKET, BY DELIVERY METHOD 3.2.4.6. ROE 3.2.4.6.1. ROE GENE THERAPY MARKET, BY VECTOR 3.2.4.6.2. ROE GENE THERAPY MARKET, BY INDICATION 3.2.4.6.3. ROE GENE THERAPY MARKET, BY DELIVERY METHOD CHAPTER 4: GLOBAL GENE THERAPY MARKET, BY VECTOR 4.1. OVERVIEW 4.2. NON-VIRAL VECTORS 4.2.1. NON-VIRAL VECTORS MARKET, BY REGION 4.2.1.1. NORTH AMERICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.2. EUROPE NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.3. ASIA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET, BY COUNTRY 4.3. VIRAL VECTORS 4.3.1. VIRAL VECTORS MARKET, BY REGION 4.3.1.1. NORTH AMERICA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.2. EUROPE VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.3. ASIA VIRAL VECTORS MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET, BY COUNTRY CHAPTER 5: GLOBAL GENE THERAPY MARKET, BY INDICATION 5.1. OVERVIEW 5.2. NEUROLOGICAL DISEASES 5.2.1. NEUROLOGICAL DISEASES MARKET, BY REGION 5.2.1.1. NORTH AMERICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.2. EUROPE NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.3. ASIA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET, BY COUNTRY 5.3. CANCER 5.3.1. CANCER MARKET, BY REGION 5.3.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 5.3.1.2. EUROPE CANCER MARKET, BY COUNTRY 5.3.1.3. ASIA CANCER MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 5.4. HEPATOLOGICAL DISEASES 5.4.1. HEPATOLOGICAL DISEASES MARKET, BY REGION 5.4.1.1. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.2. EUROPE HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.3. ASIA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.4.1.4. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET, BY COUNTRY 5.5. DUCHENNE MUSCULAR DYSTROPHY 5.5.1. DUCHENNE MUSCULAR DYSTROPHY MARKET, BY REGION 5.5.1.1. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.2. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.3. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.5.1.4. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET, BY COUNTRY 5.6. OTHER INDICATIONS 5.6.1. OTHER INDICATIONS MARKET, BY REGION 5.6.1.1. NORTH AMERICA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.2. EUROPE OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.3. ASIA OTHER INDICATIONS MARKET, BY COUNTRY 5.6.1.4. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET, BY COUNTRY CHAPTER 6: GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD 6.1. OVERVIEW 6.2. IN-VIVO GENE THERAOY 6.2.1. IN-VIVO GENE THERAOY MARKET, BY REGION 6.2.1.1. NORTH AMERICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.2. EUROPE IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.3. ASIA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3. EX-VIVO GENE THERAOY 6.3.1. EX-VIVO GENE THERAOY MARKET, BY REGION 6.3.1.1. NORTH AMERICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.2. EUROPE EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.3. ASIA EX-VIVO GENE THERAOY MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET, BY COUNTRY TABLE 01. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 02. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 03. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 04. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 05. GLOBAL GENE THERAPY MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. EUROPE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($MILLION) TABLE 07. EUROPE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($MILLION) TABLE 08. EUROPE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($MILLION) TABLE 09. EUROPE GENE THERAPY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 10. GERMANY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 11. GERMANY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 12. GERMANY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 13. FRANCE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 14. FRANCE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 15. FRANCE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 16. U.K. GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 17. U.K. GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 18. U.K. GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 19. ITALY GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 20. ITALY GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 21. ITALY GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 22. SPAIN GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 23. SPAIN GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 24. SPAIN GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 25. ROE GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 26. ROE GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 27. ROE GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 28. GLOBAL GENE THERAPY MARKET VALUE, BY VECTOR, 2023-2030, ($ MILLION) TABLE 29. NON-VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 30. NORTH AMERICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. EUROPE NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. ASIA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. MIDDLE EAST & AFRICA NON-VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. VIRAL VECTORS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 35. NORTH AMERICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. EUROPE VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. ASIA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. MIDDLE EAST & AFRICA VIRAL VECTORS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. GLOBAL GENE THERAPY MARKET VALUE, BY INDICATION, 2023-2030, ($ MILLION) TABLE 40. NEUROLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 41. NORTH AMERICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. EUROPE NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. ASIA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. MIDDLE EAST & AFRICA NEUROLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 46. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. HEPATOLOGICAL DISEASES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA HEPATOLOGICAL DISEASES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 56. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 57. EUROPE DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. ASIA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. OTHER INDICATIONS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 61. NORTH AMERICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 62. EUROPE OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. ASIA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. MIDDLE EAST & AFRICA OTHER INDICATIONS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. GLOBAL GENE THERAPY MARKET VALUE, BY DELIVERY METHOD, 2023-2030, ($ MILLION) TABLE 66. IN-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA IN-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. EX-VIVO GENE THERAOY MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 72. NORTH AMERICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 73. EUROPE EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. ASIA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. MIDDLE EAST & AFRICA EX-VIVO GENE THERAOY MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)